Welcome to the Current Issues section of the Journal of Emerging Research in Cancer Pharmacotherapy (JERCP). This page provides access to the most recent and previously published issues of the journal, featuring innovative research and clinical advancements in cancer pharmacotherapy.
Featured Articles in the Latest Issue
- Volume 1 (Issue 2) JULY– DECEMBER 2025
Research Articles
Nanocarrier-based delivery system Development and In-Vitro Evaluation of Paclitaxel in Triple-Negative Breast Cancer
Vol.1(2); Pages:1-12. Published on July-2025
Abstract
Triple-negative breast cancer (TNBC) is a virulent type of breast cancer that has few treatment choices because it does not have definite molecular targets. This paper discusses the formulation and in-vitro analysis of paclitaxel loaded nanocarrier system to enhance solubility, tumor specificity, and cytotoxicity of paclitaxel in TNBC. A modified solvent evaporation method was used to make nanoparticles, which were then characterized in terms of size, polydispersity index (PDI), zeta potential, and drug loading. Optimized formulation was found to have improved cellular uptake and two-fold cytotoxicity than free paclitaxel as tested in MDA-MB-231 cell line by MTT assay. These results indicate the delivery systems based on nanocarriers could considerably increase the therapeutic effect of paclitaxel, and this strategy represents a viable chance to improve outcomes of treatment in TNBC. These findings point to the promise of nanoparticle-based systems in addressing the issues inherent in the poor solubility and non-specific delivery of paclitaxel and forms the basis of future pre-clinical and clinical studies.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Triggered Dose System Nanoparticle Cisplatin Treatment of Refractory Ovarian Cancer: a Phase II Randomized Trial
Vol.1(2); Pages:13-23. Published on July-2025
Abstract
In this randomized controlling protocol, the encapsulation is assessed in terms of the safety and efficacy of cisplatin embedded in biodegradable lipid-based nanoparticles in patients with refractory ovarian cancer that has not responded to conventional platinum-based regimens. The 120 patients were randomly assigned and administered usual cisplatin by infusion or nanoparticle wrapped cisplatin. Progression-free survival (PFS) was the main endpoints, and the secondary endpoints were toxicity profile and quality of life. Encapsulated, nanosized cisplatin led to a 35% PFS increment, diminished nephrotoxicity, and ototoxicity, and increased toleration to therapy. In vitro analyses showed an increase in uptake into tumor and a reduction in drug exposure to other body systems. The results of this study lend credence to the clinical prospect of nanoparticlemediated cisplatin delivery in case of refractory gynecological malignancies and warrants further Phase III trials.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Multicentric Observation Pharmacogenomic Determinants of Tamoxifen Resistance in Postmenopausal Breast Cancer
Vol.1(2); Pages:24-34. Published on July-2025
Abstract
One of the challenges of postmenopausal breast cancer is the Tamoxifen resistance. A total of 450patients enrolled in this multicenter observational study in six European oncology centers were used to determine genetic polymorphisms associated with adverse therapeutic outcomes. Peripheral blood genotypes were tested to identify variants in genes CYP2D6, ESR1 and SULT1A1 influencing the metabolism and binding to receptor of tamoxifen. CYP2D6 Determinants Poor metabolizer genotypes of CYP2D6 were linked with a twofold increase in relapse risk in the three year interval as requested extensive metabolizers. The polymorphisms of ESR1 were associated with reduced sensitivity to estrogen receptor and they have been proved to be in resistance. Applying precision pharmacogenomics screening to breast cancer treatment with an emphasis on studying tamoxifen therapy, the study proposes that adding blood-based pharmacogenomic screening performed prior to tamoxifen therapy exposes patients to alternative therapeutic pathways to tamoxifen use, including aromatase inhibitors.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Phase II Trial of Efficacy of a Combination of Immune Checkpoint Inhibitors and Low-Doses of Chemotherapy in Metastatic Melanoma
Vol.1(2); Pages:35-43. Published on August-2025
Abstract
The trial was a Phase II clinical trial that assessed the efficacy of the use of low-dose dacarbazine chemotherapy combined with PD-1 inhibitor in individuals with a metastatic melanoma who were 92. The patients were randomly allocated in both the immune checkpoint inhibitor (ICI) monotherapy and combination regimen. Overall response rate (ORR) and progression-free survival (PFS) were the major endpoints. The combination arm had an ORR of 48 percent, 29 percent in the monotherapy arm, and mean PFS benefits of 4.2 months. Combination group tended to have more CD8+ T-cell infiltrate and produce more IFN-y following -immune profiling. Notably, the inclusion of chemotherapy did not make any significant difference in grade 3 or higher toxicities implying the safety profile. These results substantiate the combination regimen in the therapeutic management of melanoma and provide the basis of extended trials.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Meta-Analysis and Systematic Review of the Oral PARP Inhibitors in Advanced Prostate Cancer
Vol.1(2); Pages:44-52. Published on August-2025
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors have been highly promising agents in targeted therapy against advanced prostate cancer and particularly patients with BRCA1/2 and other homologous recombination repair (HRR) gene mutations. The study is a systematic review and meta analysis of 14 randomized control trials, which include 2865 patients that received treatment with PARP inhibitors (olaparib, rucaparib and niraparib). Key endoints overall survival (OS), radiographic progression-free survival (rPFS), and incidence of adverse events indicated a significant 5.8-month overall survival gain with PARP inhibitors, with the largest benefit in BRCA-mutated subgroups. Also, rPFS was also extended persistently. Most frequent toxicities were hematologic: most often the anemia or thrombocytopenia. The results confirm the importance of PARP inhibitors as a potentially useful anti-cancer drug against advanced prostate cancer and indicate that genomic analysis is required to select potential patients to whom the therapy can be administered.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
